Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Haiyan ChengZhou ZhangBing ZhangWen ZhangJin WangWenyu NiYingwen MiaoJiani LiuYan BiPublished in: Diabetes care (2022)
Our head-to-head study demonstrated that liraglutide enhanced impaired brain activation and restored impaired cognitive domains in patients with type 2 diabetes, whereas dapagliflozin and acarbose did not. The results expand the clinical application of liraglutide and provide a novel treatment strategy for individuals with diabetes and a high risk of cognitive decline.
Keyphrases
- cognitive decline
- mild cognitive impairment
- type diabetes
- placebo controlled
- optic nerve
- double blind
- cardiovascular disease
- open label
- white matter
- resting state
- phase iii
- clinical trial
- metabolic syndrome
- phase ii
- adipose tissue
- functional connectivity
- brain injury
- optical coherence tomography
- subarachnoid hemorrhage